Cancer discovery
-
The U. S. Food and Drug Administration approved the use of trametinib and dabrafenib in combination for patients with metastatic or unresectable melanoma with BRAF V600K or V600E mutations-the first combination therapy approved for the disease.
-
The federal budget for 2014, signed into law by President Obama in January, increases funding for the NIH, National Cancer Institute, and U. S. Food and Drug Administration, but it doesn't fully cover the losses they sustained collectively in 2013 due to sequestration.
-
Although the addition of dasatinib to letrozole improved progression-free survival in postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer compared with letrozole alone, the clinical benefit was the same for both groups.